Korian, Europe’s largest nursing home group, has removed its CEO, Yann Coleou, and replaced him with Sophie Boissard, a former civil servant. We look at why.
Korian continues its German expansion and buys the third largest German nursing home group Casa Reha for €300m. This acquisition is a success ‘on paper’ according to analysts, but the group must be careful to not overly rely on external growth.
European countries are undergoing rapid and substantial demographic and technological changes. Yet, healthcare systems are still mainly state-funded and acute-focused, as they have been for the past 70 years. This is starting to change.
Pan-European hospital group Capio reckons that productivity gains from shorter hospital stays should enable it to achieve 4% organic sales growth across its operations in Sweden, Norway, Germany and France. But tariff cuts in France and a nasty bout of flu in Germany meant it only hit 2.3% for the third quarter and 2.9% for the first nine months. Capio IPOed in June 2015. Its shares fell SEK1.25 to 53SEK on the news but still trade above the SEK48.5 IPO price.
French nursing home, Groupe Colisée, has bought two omes in North Italy. Meanwhile Korian, the largest nursing home group in Europe has bought another German group.
We hear that Labcorp, the big US lab group is the latest potential bidder to kick the types at Unilabs, the Pan-West European lab group which Rothschild has put on the block. We analyse the bidders in an endgame of consolidation.
Slick B2C medical booking system Doctolib plans to expand out of France in 2016-17. In 18 months the start up has grown to over 100 staff, signed up 5,000 doctors and dentists and claims 2m patient visits a month. But how easy is to build a Pan-European platform?
French imaging medical services group Numerix which specialises in servicing and providing X-ray machines to private sector radiologists has bought Global Imaging On Line, which handles imaging data. CEO Dider Sensay says he expects the acquisition plus investments to come to €12m for GIOL which has sales of €10m a year. Next step could be a big data acquisition.
Having taken control of reference lab Biomnis, Eurofins, the fast-growing, listed international lab group, is waving a massive peace sign at other diagnostic lab players in France with the suggestion that they could “co-invest” in the groups. But will they go along with this? Or is Eurofins likely to lose a huge slab of sales?
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
